Search results for "Ulcerative Coliti"

showing 10 items of 240 documents

Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease

2011

Objectives: Loss of intestinal barrier function plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Shedding of intestinal epithelial cells is a potential cause of barrier loss during inflammation. The objectives of the study were (1) to determine whether cell shedding and barrier loss in humans can be detected by confocal endomicroscopy and (2) whether these parameters predict relapse of IBD. Methods: Confocal endomicroscopy was performed in IBD and control patients using intravenous fluorescein to determine the relationship between cell shedding and local barrier dysfunction. A grading system based on appearances at confocal endomicroscopy in humans was devise…

MalePathologyfluoresceintight junctionPilot ProjectsCrohn's DiseaseInflammatory bowel diseaseGastroenterologyEndoscopy Gastrointestinaltumour necrosis factor0302 clinical medicineIntestinal mucosaRecurrencecolonoscopyMedizinische Fakultätgut differentiationProspective Studies1506Intestinal MucosaConfocal laser endomicroscopyIBD modelsBarrier function0303 health sciencesCrohn's diseaseMicroscopy ConfocalapoptosisGastroenterologyMiddle AgedPrognosisUlcerative colitisBarrett's oesophagus3. Good healthcell deathDisease ProgressionFemalecell shedding030211 gastroenterology & hepatologyBarrett's metaplasiagastrointestinal physiologyAdultmedicine.medical_specialtySubsequent RelapseConfocalcolorectal cancer-mucosal healing03 medical and health sciencesPredictive Value of Testscolorectal metastasesInternal medicinegastrinmedicineEndomicroscopyHumansddc:610endoscopyFluorescent Dyesulcerative colitis030304 developmental biologymagnifying colonoscopybusiness.industryInflammatory Bowel DiseaseInflammatory Bowel Diseasesmedicine.diseaseIBD basic researchbarrier functionbusiness
researchProduct

Modulation Of Beta2 and Beta3 Integrins in experimental colitis induced by iodoacetamide and enteropathogenic E.Coli

2013

Integrins can modulate the infiltration of inflammatory cells and the secretion of various inflammatory mediators, essential players in the pathogenesis of colitis. This study explores the role of beta2 and beta3 integrin signaling and their possible role in experimental colitis. A total of 160 adult male Sprague-Dawly rats were divided into 4 equal groups: methylcellulose, bacteria, iodoacetamide and iodoacetamide plus bacteria. Clinical symptoms and signs of colitis were checked daily and colonic tissues were biopsied on days 3, 14, 28, and 56 post induction. Histological studies along with histochemical analysis and polymerase chain reaction of beta2, beta3 and alphavbeta3 were performed…

MaleSettore BIO/17 - IstologiaIntegrin beta3ColitisImmunohistochemistryRatsUp-RegulationIodoacetamideRats Sprague-DawleyEnteropathogenic Escherichia coliCD18 AntigensAnimalsUlcerative colitis integrins enteropathogenic E.Coli inflammation iodoacetamideEscherichia coli Infections
researchProduct

The long-term effects of probiotics in the therapy of ulcerative colitis: a clinical study

2016

Aim: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. Method: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 pati…

MaleSettore MED/07 - Microbiologia E Microbiologia Clinicaved/biology.organism_classification_rank.specieslcsh:MedicineGastroenterologyInflammatory bowel diseaselaw.inventionProbioticchemistry.chemical_compound0302 clinical medicineLactobacillus acidophiluslawMesalamineBifidobacteriumSettore MED/12 - GastroenterologiabiologyLactobacillus salivariusMicrobiotaMedicine (all)Anti-Inflammatory Agents Non-Steroidalfood and beveragesMiddle AgedUlcerative colitisLactobacillus acidophilusTreatment Outcome030220 oncology & carcinogenesis030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleBifidobacteria; Inflammatory bowel diseases; Lactobacilli; Microbiota; Ulcerative colitis; Medicine (all); Biochemistry Genetics and Molecular Biology (all)Adultmedicine.medical_specialtyCombination therapyinflammatory bowel diseasesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesMesalazineDouble-Blind MethodBifidobacteriaInternal medicinemedicineHumansulcerative colitisAgedAnalysis of VarianceBifidobacterium bifidumUlcerative colitiBiochemistry Genetics and Molecular Biology (all)ved/biologybusiness.industryProbioticslcsh:Rbiology.organism_classificationmedicine.diseaseSettore MED/18 - Chirurgia GeneralechemistryLactobacilliLigilactobacillus salivariusColitis UlcerativeBifidobacterium bifidumbusiness
researchProduct

Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents.

2020

This is the peer reviewed version of the following article: Changes in the requirement for early surgery in inflammatory bowel disease in the era of biological agents. Journal of Gastroenterology and Hepatology (2020): 29 April, which has been published in final form at https://doi.org/10.1111/jgh.15084. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions

MaleTime FactorsDiseaseInflammatory bowel diseaseInflammatory bowel diseasesurgeryAnti-TNFBiological Factors0302 clinical medicineAnti-TNF Immunosuppressants Inflammatory bowel disease SurgeryCrohn DiseaseimmunosuppressantsRisk Factorsanti‐TNFGastroenterologyAge FactorsMiddle AgedUlcerative colitisNatural history030220 oncology & carcinogenesisCohort030211 gastroenterology & hepatologyFemaleImmunosuppressive AgentsCohort studyAdultmedicine.medical_specialtyMedicinaDisease-Free Survival03 medical and health sciencesEarly surgeryYoung AdultGastrointestinal Agentsinflammatory bowel diseaseInternal medicinemedicineHumansSurvival analysisRetrospective StudiesHepatologybusiness.industryTumor Necrosis Factor-alphamedicine.diseasedigestive system diseasesInfliximabImmunosuppressantsSurgeryColitis Ulcerativebusiness
researchProduct

Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study.

2009

International audience; BACKGROUND: Reports of an increased risk of lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease are controversial. We assessed this risk in a prospective observational cohort study. METHODS: 19,486 patients with inflammatory bowel disease, of whom 11,759 (60.3%) had Crohn's disease and 7727 (39.7%) had ulcerative colitis or unclassified inflammatory bowel disease, were enrolled in a nationwide French cohort by 680 gastroenterologists, who reported details of immunosuppressive therapy during the observation period, cases of cancer, and deaths. The risk of lymphoproliferative disorder was assessed according to thiopurine expos…

MaleTime FactorsMESH : Age DistributionMESH : Prospective StudiesMESH : AgedInflammatory bowel diseaseMESH: Proportional Hazards Models0302 clinical medicineMESH: Lymphoproliferative DisordersCrohn DiseaseRisk FactorsMESH: Risk FactorsMESH : PurinesMESH : FemaleProspective StudiesMESH: IncidenceProspective cohort studyMESH : Immunosuppressive AgentsMESH : Sex DistributionMESH: AgedMESH : Tumor Necrosis Factor-alphaCrohn's diseaseMESH: Middle AgedThiopurine methyltransferasebiologyMESH : Lymphoproliferative DisordersIncidenceMESH: Sex DistributionGeneral MedicineMESH: PurinesMiddle AgedMESH : AdultMESH : Colitis UlcerativeUlcerative colitisMESH : Risk FactorsMESH : Incidence3. Good health030220 oncology & carcinogenesisCohortDrug Therapy CombinationFemale030211 gastroenterology & hepatology[ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologyFranceMESH: Immunosuppressive AgentsImmunosuppressive AgentsCohort studyMESH : Time FactorsAdultmedicine.medical_specialtyMESH : MaleMESH: Colitis UlcerativeLymphoproliferative disordersMESH : Crohn DiseaseMESH: Multivariate Analysis03 medical and health sciencesAge DistributionInternal medicinemedicineHumansMESH : Middle AgedSex DistributionMESH : FranceMESH: Age DistributionAgedProportional Hazards ModelsMESH: HumansMESH: Crohn DiseaseTumor Necrosis Factor-alphabusiness.industryMESH : Drug Therapy CombinationMESH: Time FactorsMESH : HumansMESH : Multivariate AnalysisMESH: Adult[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterologymedicine.diseaseMESH : Proportional Hazards ModelsLymphoproliferative DisordersMESH: MaleMESH: Prospective StudiesSurgeryMESH: FranceMESH: Drug Therapy CombinationPurinesMESH: Tumor Necrosis Factor-alphaMultivariate Analysisbiology.proteinColitis UlcerativebusinessMESH: Female
researchProduct

The endoscopic spectrum of segmental colitis associated with diverticulosis.

2010

Objective  An endoscopic classification of ‘Segmental colitis associated with diverticulosis’ (SCAD) is lacking. Our aim was therefore to assess the endoscopic spectrum of SCAD, comparing it with the histological and clinical features. Method  A prospective study was performed from January 2004 to October 2007. Diagnosis of SCAD was made on the basis of specific endoscopic and histological patterns. Results  A total of 6230 consecutive colonoscopies were performed during the study period. SCAD was diagnosed in 92 (1.48%) patients, with four endoscopic patterns: pattern A, ‘crescentic fold disease’ (52.20%); pattern B, ‘Mild-to moderate ulcerative colitis-like’ pattern (30.40%); pattern C, ‘…

Malemedicine.medical_specialtyAbdominal painComorbidityGastroenterologyEndoscopy GastrointestinalInternal medicineMedicineHumansColitisIntestinal MucosaProspective cohort studyAgedbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseColitisUlcerative colitisDiverticulosisSevere inflammationDiverticulumFemalemedicine.symptombusinessScadColorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
researchProduct

Subcutaneous emphysema, pneumomediastinum and pneumoperitoneum after diagnostic colonoscopy for ulcerative colitis: a rare but possible complication …

2010

Dear Editor: Colonoscopy is regarded as a safe procedure, but complications may occur. The most dreaded are perforation and massive bleeding of the colon. The incidence of perforation is low but, despite increased experience with the procedure, it remains unchanged over time and in a large population study ranges from 0.6 to 1 per 1.000 procedures, depending on the centre and the data source. Few studies have assessed risk factors for colonoscopy-related bleeding and perforation. Gatto et al. have reported that there was a significant trend in the incidence of perforation with increasing age, people aged 75 years or older having a fourfold risk as compared to those aged 65–69 years; same re…

Malemedicine.medical_specialtyAbdominal painmedicine.medical_treatmentPerforation (oil well)ColonoscopyPneumoperitoneumPneumoperitoneumLaparotomymedicinePneumomediastinumMediastinal EmphysemaAged 80 and overmedicine.diagnostic_testbusiness.industryRisk FactorGeneral surgeryGastroenterologyColonoscopymedicine.diseaseUlcerative colitisSubcutaneous EmphysemaSurgerySettore MED/18 - Chirurgia GeneraleColitis UlcerativeLaparoscopyAged 80 and over; Colitis Ulcerative; Colonoscopy; Humans; Laparoscopy; Male; Mediastinal Emphysema; Pneumoperitoneum; Risk Factors; Subcutaneous Emphysema; Gastroenterologymedicine.symptombusinessSubcutaneous emphysemaHumanInternational Journal of Colorectal Disease
researchProduct

Five cases of de novo inflammatory bowel disease after orthotopic liver transplantation.

2006

Immunosuppression is currently the treatment of choice for severe inflammatory bowel disease (IBD). Thus, it was anticipated that the course of preexisting IBD should improve after orthotopic liver transplantation (OLT). Despite sufficient allograft immunosuppressive therapy, however, exacerbation of IBD or the development of de novo IBD after OLT were described in some cases, primarily in patients transplanted for end-stage primary sclerosing cholangitis (PSC). In addition, the development of de novo IBD in patients undergoing OLT for indications other than PSC was described. Evaluating our collective of 314 liver transplanted patients we found five patients transplanted for various indica…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentBiopsyAutoimmune hepatitisLiver transplantationGastroenterologyInflammatory bowel diseasePrimary sclerosing cholangitisInternal medicinemedicineHumansImmunosuppression TherapyHepatologybusiness.industryGastroenterologyImmunosuppressionHepatitis BMiddle Agedmedicine.diseaseUlcerative colitisdigestive system diseasesTacrolimusLiver Transplantationsurgical procedures operativeColitis UlcerativeFemalebusinessThe American journal of gastroenterology
researchProduct

Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study.

2008

Abstract Background Infliximab (IFX), the chimeric anti TNFalpha antibody, an established treatment for Crohn's disease in adults and in children, is used less frequently in ulcerative colitis (UC). Aim of the study To report the clinical course of pediatric patients with active UC receiving IFX. Patients and methods Charts of 22 patients were reviewed (13 male, 9 female): 4 with a severe UC attack refractory to systemic corticosteroids (CS); 18 with a protracted course, of which 16 CS-dependent and 2 CS-resistant. The baseline therapeutic program consisted of 3 consecutive intravenous infusions (0, 2, 6 weeks) of IFX (5 mg/kg), followed by a retreatment schedule (infusion every 8 weeks); a…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentPediatric ulcerative colitisAzathioprineGastroenterologyRefractoryInternal medicineAzathioprinemedicineHumansColitisChildColectomyRetrospective StudiesSalvage TherapyHepatologybusiness.industryRemission InductionGastroenterologyAntibodies Monoclonalmedicine.diseaseUlcerative colitisInfliximabInfliximabMulticenter studyItalyColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Inflammatory bowel disease in patients over the age of 70y. Does the disease duration influence its behavior?

2018

Introduction: The fastest growing segment of our population is that of people above 70 years of age. Elderly patients with IBD exhibit several specific problems. Our objective was to evaluate the clinical course, the side effects of the treatments and the need for surgery of elderly patients, regardless of the age of onset.Materials and Methods: This was a cross-sectional study wherein retrospective data were collected from multiple centers from seven hospitals within the Valencia metropolitan area. Data were collected on patients older than 70y with inflammatory bowel disease.Results: We identified a total of 331 patients older than 70 years of age (5.3% of patients monitored at our center…

Malemedicine.medical_specialtyDisease durationPopulationComorbiditymacromolecular substancesInflammatory bowel diseaseGastroenterology03 medical and health sciencesElderly0302 clinical medicineAdrenal Cortex HormonesNeoplasmsInternal medicinemedicineHumansImmunologic FactorsIn patientMesalamineeducationAgedRetrospective Studiesulcerative colitisAged 80 and overCrohn's diseaseeducation.field_of_studybusiness.industrymusculoskeletal neural and ocular physiologyGastroenterologyInflammatory Bowel Diseasesmedicine.diseaseUlcerative colitisCrohn's diseaseCross-Sectional StudiesLogistic ModelsSpainSurgical Procedures Operative030220 oncology & carcinogenesisDisease ProgressionFemale030211 gastroenterology & hepatologybusiness
researchProduct